Doxofylline is a xanthine derivative that inhibits phosphodiesterases (PDEs), but does not activate adenosine receptors. Doxofylline exhibits anti-asthma, anti-tussive, and bronchodilatory activities and is clinically used to treat asthma.
| Cas No. | 69975-86-6 |
|---|---|
| Purity | ≥98% |
| Formula | C11H14N4O4 |
| Formula Wt. | 266.25 |
| Chemical Name | 7-(1,3-Dioxolan-2-yl-methyl)-3,7-dihydro-1,3- dimethyl-1H-purine-2,6-dione |
| IUPAC Name | 7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione |
| Synonym | Ansimar; Maxivent; Ventax |
| Melting Point | 144-145.5°C |
| Solubility | Soluble in water, acetone, ethyl acetate, hot methanol, hot ethanol, benzene or chloroform. |
| Appearance | White Crystal Powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | D5792 MSDS PDF |
|---|---|
| Info Sheet | D5792 Info Sheet PDF |
Shukla D, Chakraborty S, Singh S, et al. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2009 Oct;10(14):2343-56. PMID: 19678793.
Cirillo R, Barone D, Franzone JS. Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors. Arch Int Pharmacodyn Ther. 1988 Sep-Oct;295:221-37. PMID: 3245738.
